See more : LQwD FinTech Corp. (LQWDD) Income Statement Analysis – Financial Results
Complete financial analysis of Takeda Pharmaceutical Company Limited (TAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Takeda Pharmaceutical Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lian Hong Art. Co., Ltd. (6755.TWO) Income Statement Analysis – Financial Results
- Millrock Resources Inc. (0V6Y.L) Income Statement Analysis – Financial Results
- China Energine International (Holdings) Limited (1185.HK) Income Statement Analysis – Financial Results
- Soyo Group Inc. (SOYO) Income Statement Analysis – Financial Results
- Temple & Webster Group Ltd (TPW.AX) Income Statement Analysis – Financial Results
Takeda Pharmaceutical Company Limited (TAK)
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,263.76B | 4,027.48B | 3,569.01B | 3,197.81B | 3,291.19B | 2,097.22B | 1,770.53B | 1,732.05B | 1,807.38B | 1,777.82B | 1,691.69B | 1,557.27B | 1,508.93B | 1,419.39B | 1,465.97B | 1,538.34B | 1,374.80B | 1,305.17B | 1,212.21B | 1,122.96B | 1,086.43B | 1,046.08B | 1,005.06B | 963.48B | 923.13B |
| Cost of Revenue | 1,431.51B | 1,244.07B | 1,106.85B | 994.31B | 1,089.76B | 659.69B | 495.92B | 558.76B | 535.41B | 520.99B | 490.26B | 447.63B | 433.19B | 317.58B | 285.06B | 289.54B | 278.63B | 279.66B | 282.10B | 279.18B | 269.40B | 300.34B | 337.85B | 384.01B | 432.33B |
| Gross Profit | 2,832.26B | 2,783.41B | 2,462.16B | 2,203.50B | 2,201.42B | 1,437.53B | 1,274.61B | 1,173.30B | 1,271.97B | 1,256.83B | 1,201.42B | 1,109.64B | 1,075.74B | 1,101.80B | 1,180.90B | 1,248.79B | 1,096.17B | 1,025.51B | 930.11B | 843.78B | 817.04B | 745.74B | 667.21B | 579.47B | 490.80B |
| Gross Profit Ratio | 66.43% | 69.11% | 68.99% | 68.91% | 66.89% | 68.54% | 71.99% | 67.74% | 70.38% | 70.70% | 71.02% | 71.26% | 71.29% | 77.63% | 80.55% | 81.18% | 79.73% | 78.57% | 76.73% | 75.14% | 75.20% | 71.29% | 66.38% | 60.14% | 53.17% |
| Research & Development | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.30B | 325.44B | 312.30B | 345.93B | 382.10B | 341.56B | 324.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.40B | 450.96B | 811.62B | 810.71B | 640.20B | 666.68B | 834.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.21B | 105.25B | 175.52B | 0.00 | 94.52B | 94.01B | 108.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1,053.82B | 997.31B | 886.36B | 875.66B | 964.74B | 717.60B | 628.11B | 619.06B | 650.77B | 612.61B | 556.21B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Other Expenses | 834.44B | 662.27B | 588.87B | 362.74B | 643.90B | 908.87B | 707.38B | 705.13B | 795.22B | 1,003.99B | 720.59B | 5.81B | 0.00 | 3.78B | 735.00M | 12.13B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 0.00 | 353.37B | 0.00 |
| Operating Expenses | 2,618.18B | 2,292.90B | 2,001.32B | 1,694.24B | 2,101.02B | 1,277.17B | 1,032.82B | 1,017.43B | 1,141.15B | 1,386.09B | 1,062.15B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 385.96B | 353.37B | 319.36B |
| Cost & Expenses | 4,049.69B | 3,536.97B | 3,108.16B | 2,688.54B | 3,190.78B | 1,936.86B | 1,528.74B | 1,576.18B | 1,676.55B | 1,907.08B | 1,552.41B | 1,434.76B | 1,243.91B | 1,052.30B | 1,045.75B | 1,231.87B | 951.68B | 846.67B | 809.40B | 737.68B | 714.80B | 735.40B | 723.82B | 737.38B | 751.69B |
| Interest Income | 11.29B | 62.91B | 23.70B | 105.52B | 27.83B | 6.62B | 39.54B | 12.27B | 21.65B | 15.36B | 49.30B | 16.30B | 6.30B | 1.73B | 1.98B | 11.38B | 62.06B | 56.24B | 34.21B | 18.10B | 10.90B | 10.13B | 9.61B | 9.93B | 0.00 |
| Interest Expense | 119.54B | 169.70B | 166.61B | 248.63B | 165.01B | 48.16B | 31.93B | 23.25B | 31.93B | 32.88B | 30.72B | 3.32B | 1.88B | 1.34B | 1.43B | 1.62B | 333.00M | 247.00M | 365.00M | 334.00M | 359.00M | 420.00M | 759.00M | 1.02B | 1.19B |
| Depreciation & Amortization | 728.00B | 664.40B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B | 181.24B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.61B | 33.36B |
| EBITDA | 900.33B | 1,156.46B | 1,183.21B | 983.72B | 880.33B | 464.22B | 359.96B | 296.88B | 349.85B | 148.39B | 368.18B | 351.18B | 421.82B | 479.63B | 537.64B | 518.25B | 608.87B | 654.45B | 547.05B | 472.66B | 474.59B | 462.28B | 402.62B | 297.70B | 237.32B |
| EBITDA Ratio | 21.12% | 30.02% | 29.49% | 36.73% | 20.90% | 17.95% | 24.36% | 22.48% | 19.36% | 8.35% | 23.96% | 22.55% | 27.95% | 34.12% | 36.67% | 28.78% | 44.53% | 48.03% | 43.89% | 42.75% | 44.48% | 42.00% | 38.20% | 30.16% | 27.31% |
| Operating Income | 214.08B | 490.51B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B | 130.83B | -129.25B | 139.27B | 122.51B | 265.03B | 367.08B | 420.21B | 306.47B | 423.12B | 458.50B | 402.81B | 385.28B | 371.63B | 310.69B | 281.24B | 226.10B | 171.44B |
| Operating Income Ratio | 5.02% | 12.18% | 12.91% | 15.93% | 3.05% | 9.77% | 13.66% | 9.00% | 7.24% | -7.27% | 8.23% | 7.87% | 17.56% | 25.86% | 28.66% | 19.92% | 30.78% | 35.13% | 33.23% | 34.31% | 34.21% | 29.70% | 27.98% | 23.47% | 18.57% |
| Total Other Income/Expenses | -161.28B | -115.42B | -158.27B | -143.03B | -161.16B | -77.36B | -24.58B | -12.52B | -10.29B | -16.18B | -1.60B | 10.56B | -12.55B | 4.49B | -4.38B | 92.08B | 153.72B | 166.88B | 115.15B | 55.82B | 74.51B | 121.21B | 92.18B | 36.97B | 31.32B |
| Income Before Tax | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 94.90B | 217.21B | 143.35B | 120.54B | -145.44B | 158.85B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.10B | 446.14B | 431.90B | 373.43B | 263.08B | 202.76B |
| Income Before Tax Ratio | 1.24% | 9.31% | 8.48% | 11.45% | -1.85% | 4.52% | 12.27% | 8.28% | 6.67% | -8.18% | 9.39% | 8.33% | 16.73% | 26.18% | 28.37% | 25.91% | 41.96% | 47.92% | 42.73% | 39.28% | 41.07% | 41.29% | 37.15% | 27.30% | 21.96% |
| Income Tax Expense | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.50B | 27.83B | 37.06B | -2.40B | 49.29B | -3.88B | 125.21B | 121.33B | 115.67B | 161.35B | 218.77B | 285.84B | 201.36B | 160.23B | 157.91B | 157.49B | 134.89B | 114.15B | 81.45B |
| Net Income | 144.07B | 317.02B | 230.06B | 376.01B | 44.24B | 109.13B | 186.89B | 114.94B | 80.17B | -145.78B | 106.66B | 131.24B | 124.16B | 247.87B | 297.74B | 234.39B | 355.45B | 335.81B | 313.25B | 277.44B | 285.26B | 271.76B | 235.66B | 146.86B | 119.63B |
| Net Income Ratio | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% | 5.20% | 10.56% | 6.64% | 4.44% | -8.20% | 6.30% | 8.43% | 8.23% | 17.46% | 20.31% | 15.24% | 25.85% | 25.73% | 25.84% | 24.71% | 26.26% | 25.98% | 23.45% | 15.24% | 12.96% |
| EPS | 91.16 | 204.29 | 147.14 | 240.72 | 28.41 | 56.75 | 119.67 | 73.58 | 51.13 | -92.69 | 67.55 | 94.11 | 78.65 | 157.01 | 188.60 | 144.91 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| EPS Diluted | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 56.43 | 118.78 | 73.13 | 50.86 | -92.69 | 67.47 | 94.09 | 78.63 | 156.98 | 188.57 | 144.90 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| Weighted Avg Shares Out | 1.58B | 1.55B | 1.56B | 1.56B | 1.56B | 1.92B | 1.56B | 1.56B | 1.57B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Weighted Avg Shares Out (Dil) | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 1.93B | 1.57B | 1.57B | 1.58B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by...
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients...
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat (TAK-935) plus standard of care versus placebo plus standard of...
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an...
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently...
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its partnership with Partners In Health (PIH), an international nonprofit organization, to support a new initiative with PIH that aims to address social determinants of health and improve access to care...
Celiac Disease Market and Epidemiology Analysis 2018-2034 with Detailed Profiles of Marketed and Pipeline Drugs, Including KAN-101 (Kanyos Bio) and TIMP-GLIA/TAK 101 (Takeda)
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Celiac Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major Celiac disease markets reached a value of US$ 584.9...
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy...
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with...
Source: https://incomestatements.info
Category: Stock Reports